Acelrx pharmaceuticals inc (ACRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net loss

-55,491

-53,240

-51,375

-51,102

-49,231

-47,149

-44,476

-45,031

-47,549

-51,508

-51,305

-49,694

-47,727

-43,157

-44,021

-27,550

-25,354

-24,399

-27,671

-32,069

-33,748

-33,353

-1,766

-13,423

-20,295

-23,426

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization

317

312

307

252

277

289

282

260

221

151

93

53

28

7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest (income) expense on liability related to royalty monetization

-3,787

-1,337

1,242

5,141

9,132

10,341

11,510

11,365

10,979

10,721

10,396

10,029

9,744

9,382

9,067

6,948

4,624

2,428

0

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization

1,827

1,668

1,293

1,016

754

575

791

1,089

1,413

1,744

1,895

1,971

2,020

2,052

2,027

2,016

2,008

1,984

1,899

1,545

1,192

866

623

623

614

593

0

0

0

Non-cash interest expense related to debt financing

884

712

595

503

531

613

694

1,138

1,355

1,265

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium/discount on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-110

-123

-164

-216

-255

-261

-245

-202

0

0

0

Non-cash interest expense related to debt financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

869

-

730

746

660

553

597

468

440

442

0

0

0

Restructuring costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

5,096

5,057

5,011

5,493

5,195

5,168

4,990

4,200

4,230

4,294

4,311

4,371

4,438

4,479

4,598

4,691

4,657

5,010

5,192

5,220

5,003

4,440

4,112

3,789

3,697

3,479

0

0

0

Revaluation of put option and PIPE warrant liabilities

-

-

-

-

-

-

-

-

-

-

-160

-317

-195

-767

55

-562

-351

-2,136

-607

-7,469

-9,846

-7,040

-8,337

1,349

12,962

14,071

0

0

0

Other

512

773

617

334

319

201

342

274

225

198

3

3

2

-17

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Revaluation of put option and PIPE warrant liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

346

383

57

-552

-551

-1,484

-1,156

-1,297

-1,936

-4,300

-666

-2,115

-498

2,547

-15,367

4,185

3,206

3,286

0

0

0

-

-

-

-

-

-

-

-

Inventories

1,755

3,392

2,979

2,181

1,737

-102

40

-639

-908

-920

-290

252

942

1,688

1,384

1,328

910

466

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-1,311

465

717

921

1,615

850

164

110

52

-175

-87

-205

-442

-975

184

-1,087

542

783

-428

1,216

-301

-137

106

-412

-1,020

-1,132

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

0

0

0

Accounts payable

32

-19

898

548

1,149

458

492

776

443

309

-105

-1,826

-1,909

-437

-334

1,439

1,084

-786

-1,002

-1,201

500

90

1,621

1,500

-1,756

106

0

0

0

Accrued liabilities

741

1,141

1,151

1,595

1,378

922

235

-1,600

-2,515

-1,301

-845

1,143

2,103

639

1,798

133

-1,068

325

329

-105

1,764

-126

-889

100

-1,495

-760

0

0

0

Operating lease liabilities

-729

-701

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-341

-219

-326

-329

-228

-362

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

296

-

1,072

2,324

1,568

784

566

-717

-303

-217

0

0

0

-

-

-

-

Deferred rent

-

-

-

-

-

113

175

468

587

360

171

-148

-197

-202

-345

-331

-319

-284

-101

-52

-6

-22

-38

-78

-116

-113

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-15,433

-

-35,869

-35,951

-35,073

-34,456

0

0

0

-

-

-

-

Net cash used in operating activities

-52,304

-51,180

-46,015

-40,850

-34,941

-29,075

-26,761

-27,244

-29,604

-29,765

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash flows from investing activities:
Purchase of property and equipment

2,885

3,470

3,474

2,222

1,269

819

483

831

2,077

2,405

4,334

5,373

4,066

3,720

2,215

870

1,130

1,456

1,871

4,440

4,878

5,505

6,677

5,093

4,378

3,287

0

0

0

Purchase of investments

108,954

100,068

99,638

45,870

33,434

30,558

20,409

20,409

8,560

7,565

0

0

0

-

-

-

-

7,266

9,810

18,094

18,539

17,430

17,189

14,866

21,003

28,009

0

0

0

Proceeds from maturities of investments

97,555

66,975

47,700

36,600

24,400

20,500

0

0

0

-

0

1,000

2,720

6,525

10,240

16,990

18,260

16,925

15,740

17,240

18,369

17,159

16,773

14,910

16,591

24,376

0

0

0

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

12,332

-

4,059

-5,294

-5,048

-5,776

0

0

0

-

-

-

-

Net cash provided by investing activities

-14,284

-36,563

-55,412

-11,492

-10,303

-10,877

-6,392

-17,640

-9,637

-9,970

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash flows from financing activities:
Payment of long-term debt

-

3,470

5,477

7,426

7,919

7,718

9,225

7,276

5,377

3,514

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

16,345

0

0

0

Net proceeds from issuance of common stock through equity plans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,951

-

176

1,599

1,678

1,869

2,662

2,253

2,233

1,757

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

59,386

-

56,611

-641

11,678

11,869

0

0

0

-

-

-

-

Net proceeds from issuance of common stock in connection with equity financings

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock through equity plans

691

743

1,656

1,502

1,347

1,218

361

388

399

351

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of employee tax obligations related to vesting of restricted stock units

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

17,162

14,452

65,810

84,140

74,953

75,025

22,783

16,009

10,512

12,327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net increase (decrease) in cash and cash equivalents

-49,426

-73,291

-35,617

31,798

29,709

35,073

0

0

0

-

-

-

-

-27,612

-2,580

61,958

56,285

47,884

24,801

-41,886

-28,443

-28,363

9,446

55,809

40,508

40,469

0

0

0

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment in Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-